anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: microbiology, molecular biology, genetic engineering. SUBSTANCE: invention provides preparing the strains of an attenuated bacterium Salmonella containing a promoter nirB operatively bound with DNA sequence encoding a heterological protein of a pathogenic microorganism. Method involves preparing a DNA-constructor containing nirB-promoter operatively bound with DNA-sequence encoding a heterological protein of a pathogenic microorganism, transformation of an attenuated strain of bacterium Salmonella with the indicated DNA-constructor, growing transformed bacteria on suitable nutrient medium and a selection of the end strain. Invention provides also a vaccine against sickness caused by pathogenic microorganism and containing a pharmaceutically acceptable carrier of vehicle, and a strain of an attenuated bacterium Salmonella as an active component obtained by a method indicated in an invention. Vaccine can be used for prophylaxis of both human and animals. EFFECT: improved method of vaccine and strain preparing. 7 cl, 1 tbl, 1 ex, 5 dwg
Over 50% of Native American children are overweight or obese by 5th grade, with similar rates found among Hispanics. Native American children have been estimated to have 9 times the diabetes rates of non-Hispanic Whites, suggesting an impending public health crisis without action. Recent research has demonstrated that the 'obesity gap' facing minority students is largely due to summer weight gain, with rapid increases ages 7-11. However, statewide in Arizona, only 22% of children participate in summer activities, despite 65% of parents expressing interest. Thus, we know which populations are at highest risk, at what developmental age changes occur most rapidly and that interventions are most needed in the summer, but that this need is not being met. A modest amount of research has evaluated summer programming, but almost none among Native Americans/Hispanics.

In 2004, the CDC developed a 'Summer Scorecard' intervention, a partnership with local businesses to provide children with a 'scorecard' of subsidized or free local activities. The Summer Scorecard program has not been tested among Hispanic and Native American children. Therefore, the current study propose to assess the effectiveness of the VSS among children ages 7-11 in the 4 highest risk elementary schools in the study area utilizing a randomized design. Two schools will participate in the first summer, and the remaining two children will participate in the second summer. Primary outcomes include objectively measured participation, body composition (BMI percentile), physical activity, sedentary behavior, reported barriers to physical activity and self-efficacy using survey instruments previously developed and tested by the Centers for Disease Control and Prevention. It is hypothesized that children participating in the summer program will increase their physical activity, self-efficacy, reduce their reported barriers to physical activity. In addition, it is hypothesized that they will show reduction in BMI percentile score compared to averages in their school and the school district.
Technologies for managing a treatment program include a treatment management server, smart pills, and patient computing devices. The treatment management server is configured to generate treatment data usable by the smart pills to control a release of one or more drugs in patients. The treatment management server is also configured to transmit the treatment data to the smart pills, obtain physiological data associated with the patients, identify a preferred physiological response among the patients based on the physiological data, and identify the treatment data associated with the preferred physiological response. The smart pills are configured to obtain the treatment data, release one or more drugs into the patients based on the treatment data, sense physiological conditions in the patients, and transmit the physiological conditions to the treatment management server. The patient computing devices facilitate communication between the treatment management server and the smart pills. Other embodiments are described.
Provided is an agonist for healing living organisms capable of accelerating regenerating ability of living organisms relating to healing of damages of cells and tissues due to toxicity of drugs or injuries, and having a high safety, without having any side-effect even being administered for long periods. This objective is attained by providing an agonist for healing living organisms containing a mixture of a culture obtained by cultivating a microorganism belonging to Aureobasidium sp. and a mycelium as effective component. The present invention is preferably used for reducing side-effects of anticancer drugs. Moreover, the present invention is preferably used for accelerating healing of injuries. Furthermore, the present invention is preferably used for accelerating normalization of glycaemia value or improving illness of leukemia.
Patients will receive daily left prefrontal transcranial magnetic stimulation (TMS), 120% MT, 3000 pulses/session, for 30 sessions. They will have EEG and the TMS will be delivered at their individual alpha frequency (IAF) (8-12 Hz) and the first TMS pulse in each train of 40 pulses will be synchronized with the EEG so that the TMS pulse fires during the rising phase of the alpha rhythm.
MII will not go under polar body biopsy. On day 5, 6 or 7, the resulting blastocyst will be biopsied.
OBJECTIVE: To evaluate the quality of life before and after video-assisted thoracoscopic plication of relaxed dome of diaphragm.
MATERIAL AND METHODS: The study included 17 patients operated on for unilateral relaxation of diaphragm. We analyzed quality of life in preoperative period, 1, 3, 6 and 12 months after surgery using the SF-36 and EuroQ-5D-5L questionnaires. To assess the impact of abnormality on respiratory function, we estimated diaphragm position, spirometry data and SGRQ scores.
RESULTS: FVC increased by 16.5% after 1 month, 19.5% after 6 months and 20.1% after 12 months. In addition, FEV1 significantly increased (by 12.6% after 1 month, 10.1% after 6 months and 12.7% after 12 months). Mean values of diaphragm elevation in postoperative period decreased by 25.5-25.6%. According to the SF-36 and EuroQ-5D-5L questionnaires, physical and psychological health components significantly increased within a month after surgical treatment. According to the SGRQ questionnaire, influence of disease on overall status decreased a month after surgery as evidences by lower total score (p<0.05).
CONCLUSION: Objective and survey data revealed significant improvement in quality of life after surgery. A trend towards higher quality of life was demonstrated by all questionnaires in a month after surgery.
BACKGROUND: This research aims to assess the demographic characteristics, prevalence, outcomes, and complications in chronic kidney disease (CKD) patients following mandible fractures in the United States using a nationally representative database.
METHODS: We analyzed data from the National Inpatient Sample from 2010 to 2019 in the United States. Patients with mandible fractures were categorized into three groups based on the International Classification of Diseases, Ninth and Tenth Revisions (ICD-9-CM and ICD-10-CM): end-stage renal disease (ESRD), non-ESRD CKD, and healthy kidney function. Chi-squared tests and analysis of variance (ANOVA) were used to compare these groups. Additionally, multivariate regression analysis was performed to determine whether CKD is an independent risk factor for complications in patients with mandible fractures.
RESULTS: A total of 38,481 patients in the United States were estimated to have experienced mandible fractures between 2010 and 2019. The incidence rate of non-ESRD CKD in patients with mandible fractures significantly increased over time, while the prevalence of ESRD remained stable during the ten-year period. Compared to the healthy kidney function group, patients with chronic kidney disease exhibited higher hospital costs, longer hospitalization durations, and higher in-hospital mortality rates. Additionally, they had greater odds ratios for most of the investigated complications.
CONCLUSIONS: This study revealed a steady annual increase in the morbidity rate of non-ESRD CKD among patients with mandible fractures, while ESRD prevalence remained stable over ten years. We observed a close association between chronic kidney disease and the prognosis of patients with mandible fractures. Clinicians should prioritize preventive measures and appropriate management of mandibular fractures in patients with CKD.
Tuberous sclerosis complex (TSC) is a rare inherited disease with the potential to affect virtually every organ system. Clinical presentation is age- and partly sex-dependent and varies broadly with respect to disease manifestations including treatment-refractory epilepsy, intellectual disability and TSC-associated neuropsychiatric disorders, chronic kidney disease or progressive lung function decline. Given the complexity of this disease, multidisciplinary care in specialized TSC centres is recommended. We aimed to elucidate the state of knowledge of patients/caregivers and physicians on individual disease manifestations. We further examined whether the association to a TSC centre has an impact on the comprehensive consideration of potential disease manifestations. Therefore, a survey was performed in a cohort of German TSC patients and their physicians. Complete information was available for 94 patients with a median age of 18 years [range 1-55] and a sex distribution of 53.2% (male): 48.8% (female). Using almost identical questionnaires for patients/caregivers and their respective physician, there was a good correlation for disease assessments associated with relevant morbidity and mortality like epilepsy, renal angiomyolipoma, cardiac rhabdomyomas or intellectual disability. Correlation was moderate for several neuropsychiatric disorders and only poor for hypomelanotic macules, dental pits or retinal achromic patches. Estimation of overall disease severity using a numeric rating scale correlated highly significantly (Pearson correlation coefficient = 0.767; p < 0.001) between patients/caregivers and physicians. In general, physicians more likely quoted items as 'unknown' than patients (822 answers vs. 435 answers in the respective groups). Questionnaires completed by physicians who were associated with a specialized TSC centre declared a significantly lower proportion of items as unknown (mean 8.7% vs. 20.5%; p < 0.001). These findings indicate that patients treated by specialized TSC centres seem to obtain a more comprehensive surveillance. Furthermore, it shows that there were reasonable surveillance strategies in general and sufficient patient/caregiver interaction and education in the examined cohort. However, for the most prominent disease characteristics there was a good awareness within both the patients/caregivers and the physicians group.
BACKGROUND: Immune response plays a vital role in the initiation and development of chronic kidney disease (CKD). Detailed mechanisms and specific immune-related biomarkers of CKD need further clarification. We aimed to identify and characterize immune-related infiltrates that are implicated in the CKD development using a bioinformatics method.
METHODS: The expression profiles of GSE66494 dataset were acquired from the Gene Expression Omnibus (GEO) database. Patients with CKD were divided into low- vs. high-immune subtypes based on their immune score. Based on such analysis, we identified differentially expressed genes (DEGs) of low- and high-immune subtypes. The weight gene co-expression network analysis (WGCNA) was used to identify immune-associated modules between two subtypes. The gene set enriched (GSEA) and variation (GSVA) analyses were correlated with their functional types using the molecular complex detection (MCODE) method. Finally, the immune infiltration landscape between subtypes was revealed using the xCell algorithm.
RESULTS: The total number of 131 differentially expressed immune-related genes (DEIRGs) were identified between low- vs. high-immune subtypes. Out of them GSEA/GSVA results identified and enriched immune- and inflammation-related pathways. In particular, GSVA results indicated that immune-related pathways were activated in high-immune subgroups. The core DEIRG genes that were identified to be involved in CKD development included: the protein tyrosine phosphatase receptor type C (PTPRC; also known as CD45) regulating cell growth and differentiation, an early activation marker (CD69), co-receptor for T cell receptor (CD8A), and T cell co-stimulatory signal (CD28). These core DEIRD genes were further verified by the GSE96804 dataset. We also found a higher proportion of immune cells infiltrating the high-immune subgroup. Furthermore, the four core genes were positively correlated with most immune cell types.
CONCLUSION: Among 131 DEIRG genes, four genes (PTPRC, CD69, CD8A, and CD28) were identified as potential biomarkers associated with the immune cell infiltration in CKD patients, which may provide a novel insight for immunotherapy for CKD.
OBJECTIVE: Postpartum depression (PPD) is a common complication after childbirth. Weight misperception can lead to self-esteem issues and mental health problems, especially in women and adolescents. The aim of this study was to investigate the association between weight perception before and during pregnancy and the status of PPD in Southern China.
METHODS: From October 2021 to November 2023, a multi-stage sampling method was used to recruit 2169 eligible mothers aged 18-49 who had delivered live-born singleton infants within 3 to 180 days postpartum. Anthropometric measurements and face-to-face questionnaire surveys were conducted to collect data. The Kappa test was used to assess the agreement between actual and perceived weight. The generalized linear model incorporating multiplicative interaction analysis was applied to explore the associations among variables.
RESULTS: The prevalence of PPD status was 18.0%. Among women, 35.2% perceived their pre-pregnancy weight (PPW) as abnormal, while 33.1% perceived their gestational weight gain (GWG) as inappropriate. There was poor agreement between maternal actual and perceived PPW/GWG (Kappa = 0.366, p < 0.001; Kappa = 0.188, p < 0.001), with 27.8% of women misperceiving their PPW and 52.1% misperceiving their GWG. The results of the general linear model indicated that women who perceived their PPW as underweight (β = 0.70, p = 0.016) or overweight/obese (β = 0.86, p < 0.001), as well as those who perceived their GWG as excessive (β = 0.47, p = 0.028) were more likely to exhibit PPD status. The interaction analysis results showed that those who perceived their PPW as underweight and their GWG as insufficient (β = 1.75, p = 0.020), as well as those who perceived their PPW as overweight/obese and their GWG as excessive (β = 0.90, p = 0.001) had a positive interactive effect on the occurrence of PPD status, while underestimating PPW and GWG may be a protective factor against PPD status (β = -1.03, p = 0.037).
CONCLUSION: These findings support that maternal weight perception plays a role in the development of PPD status. Further improvement is needed in personalized health education for weight management, both prior to and throughout the pregnancy period. This can help women reduce weight anxiety, better understand their body image, and potentially lower the risk of developing PPD.
The invention discloses a light-driven nanometer motor group for tumor photothermal therapy. The nano motor is a test tube-shaped gold-copper nano particle, and one end of the hollow gold tube is sealed by a copper rod. The nanomotor exhibits autonomous propulsion, the speed of which can be increased with the irradiation intensity of the near infrared light. Under near-infrared illumination, nanomotors are caused to cluster at the center of the near-infrared illumination. The size and the response time of the nano motor cluster can be easily controlled by adjusting the irradiation time and the power density of the near infrared light, and the mass center of the cluster can be guided to move by changing the position of the near infrared irradiation point, so that the accurate control of the cluster motion is realized. The nano motor clusters show good photo-thermal treatment effect under external near-infrared irradiation, and when the nano motor clusters are used for photo-thermal treatment, a photo-thermal treatment platform is provided, and efficient tumor cell eradication can be achieved.
The present invention relates to a globeflower-Vc double-layer buccal tablet and a preparation method thereof. The globeflower-Vc double-layer buccal tablet comprises a globeflower layer in which the globeflower is used as the main component and a Vc layer in which the Vc is used as the main component. The preparation method of the double-layer buccal tablet comprises the steps of respectively granulating the globeflower and the Vc, and tabletting the globeflower and the Vc by a special-shaped multilayer tabletting machine. The globeflower-Vc double-layer buccal tablet with the efficacy of clearing away heat and toxic material, clearing heat from the throat, wetting the whistle, etc. can be used for preventing upper respiratory tract infection, tonsillitis, mouth sore, throat turgescence, otalgia, etc. and has adjuvant curative effect for people with stomatitis. The double-layer buccal tablet has the advantages of scientific and reasonable preparation method, and convenient administration and portability, and is a good requisite health-care product for travel and domesticity.
The invention relates to a verapamil hydrochloride film-controlled slow-release pellet capsule. A slow-release film of the verapamil hydrochloride film-controlled slow-release pellet utilizes Eurdragit NE30D as a film-formation material. A pellet core of the verapamil hydrochloride film-controlled slow-release pellet contains sodium carboxymethyl starch having high expansibility, and also contains a pharmaceutically-acceptable common excipient for the slow-release pellet, wherein preferably, the excipient comprises microcrystalline cellulose, and the pellet core comprises 5 to 20wt% of sodium carboxymethyl starch. The slow-release film comprises Eurdragit NE30D and talcum powder as an antiplastering aid, wherein preferably, a ratio of Eurdragit NE30D to talcum powder is 30: 4 and a film weight increasing ratio is in a range of 19 to 35%. The verapamil hydrochloride film-controlled slow-release pellet comprises the pellet core containing sodium carboxymethyl starch having high water expansibility and thus after absorbing water, the verapamil hydrochloride film-controlled slow-release pellet obviously expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the verapamil hydrochloride film-controlled slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept in the period of validity.
An asymmetric membrane, osmotic, delivery device having coated macroparticulate solubility modifiers. The device comprises a beneficial agent, an osmagent, a coated macroparticulate solubility modifier and an asymmetric membrane that surrounds the device components. The device is useful for dispensing a beneficial agent to an aqueous environment of use. The coated macroparticles modify the solubility of the beneficial agent so that its release can be controlled. The larger size of the solubility modifier macroparticles provides, for example. a longer release duration than would have been possible with a smaller size.
Oral intake of placebo will be given on a daily basis in a single-blind manner one day before the first day of RT and continued for 8 weeks. The placebo group received 3 soft gel placebo capsules containing gelatin three times a day.
The invention concerns a structural peptide, identified by antibodies directed against a polypeptide, comprising the 2-45 amino acid sequence of the N-terminal end of the Core or nucleocapsid (p21) of the hepatitis C virus (HCV) or any variant of said virus, excluding any protein or peptide compound comprising or consisting of said N-terminal end. The invention is characterised in that it comprises a tertiary structure consisting of at least a first peptide fragment having a secondary structure in .alpha. helix, a second peptide fragment having a secondary structure in .alpha. helix and a third peptide bond fragment linking the two .alpha. helixes, these two .alpha. helixes being substantially perpendicular to each other in space. This peptide can be used for detecting antibodies directed against the p21 protein of HCV, for detecting all or part of the RNA of HCV and for preparing a diagnostic, prophylactic or therapeutic composition for detecting, preventing or treating an HCV infection.
Participants assigned to this condition will receive no intervention. They may continue on current medication regimens (no major changes) but may not be enrolled in psychological treatments. They will be evaluated weekly via phone call with primary caregiver. At the conclusion of this 10-week wait list period all participants assigned to this condition will receive RFP-C treatment.
Although heterotopic pancreas usually occurs in the stomach and rarely presents as a submucosal tumor, an accurate preoperative diagnosis is often difficult because of the variety of clinical symptoms and findings depending on the size and location of the lesion. We experienced a case of gastric type III heterotopic pancreas presenting as a gastric adenomyoma in the antrum of the stomach. A 62-year-old woman visited a local hospital for epigastric discomfort. An esophagogastroduodenoscopy study indicated a submucosal tumor in the greater curvature of the gastric antrum. The patient underwent surgical resection of the tumor because it was enlarged. The histological sections of the resected specimen showed that the tumor was composed of ductular structures lined by tall columnar epithelia and a prominent smooth muscle stroma with no atypical cells. The tumor was compatible with Heinrich's type III heterotopic pancreas, which presented as an adenomyoma of the stomach. These findings provide useful histological features and some insight into a better understanding of the embryonic origin and development of adenomyoma and heterotopic pancreas in the antrum of the stomach.
There has been only limited experience with overdosage of eptifibatide. There were 8 patients in the IMPACT II study, 9 patients in the PURSUIT study and no patients in the ESPRIT study who received bolus doses and/or infusion doses more than double those called for in the protocols. None of these patients experienced an intracranial bleed or other major bleeding. 

Eptifibatide was not lethal to rats, rabbits, or monkeys when administered by continuous intravenous infusion for 90 minutes at a total dose of 45 mg/kg (about 2 to 5 times the recommended maximum daily human dose on a body surface area basis). Symptoms of acute toxicity were loss of righting reflex, dyspnea, ptosis and decreased muscle tone in rabbits and petechial hemorrhages in the femoral and abdominal areas of monkeys. 

From in vitro studies, eptifibatide is not extensively bound to plasma proteins and thus may be cleared from plasma by dialysis.